Rami Manochakian: Neoadjuvant osimertinib in stage I-IIIA EGFRm NSCLC did not meet primary endpoint
Rami Manochakian shared a post on X:
”Hot off the press.
Authors: Collin M. Blakely, Anatoly Urisman, Matthew A. Gubens, Claire K. Mulvey, Greg M. Allen, Stephen C. Shiboski, Julia K. Rotow, Turja Chakrabarti, D. Lucas Kerr, Jacqueline V. Aredo, Bianca Bacaltos, Megan Gee, Lisa Tan, Kirk D. Jones, W. Patrick Devine, Robert C. Doebele, Dara L. Aisner, Tejas Patil, Erin L. Schenk, Trever G. Bivona, Jonathan W. Riess, Melissa Coleman, Johannes R. Kratz, David M. Jablons.
Just published at Journal of Clinical Oncology.
Results of phase 2 clinical trial (27 patients) of neoadjuvant osimertinib in stage I-IIIA EGFRm non-small cell lung cancer. Study DID NOT meet primary endpoint.
MPR rate: 14.8%.”
Source: Rami Manochakian/X
Rami Manochakian is a thoracic medical oncologist at Mayo Clinic, Florida. He specializes in thoracic malignancies, including lung cancer, mesothelioma, and thymic tumors, he has dedicated his career to advancing the field of oncology. He is also recognized as a leader in medical education, serving in various educational roles at Mayo Clinic and national and international medical societies, including ASCO, ALA, and IASLC.